<DOC>
	<DOCNO>NCT01193699</DOCNO>
	<brief_summary>The purpose study identification maximum tolerate dose ( MTD ) investigational medicinal product . Moreover safety tolerability assess exploratory analysis efficacy biomarker modulation perform .</brief_summary>
	<brief_title>Safety Study Pegylated Interferon Alpha 2b Treat Polycythemia Vera</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Written inform consent obtain prior study specific screen activity able comply protocol . 2 . Patients age ≥18 year 3 . Confirmed diagnosis PV accord either WHO criterion ( 2008 , appendix 6 ) PSVG ( appendix 7 ) criterion plus JAK2 positivity , include newly diagnose , pretreated cytoreductive therapy . 4 . Eastern Cooperative Oncology Group performance status ≤ 2 5 . If female childbearing potential negative urine pregnancy test result within 7 day prior schedule first application investigational product agree employ adequate birth control measure duration study . Exclusion criterion : 1 . Diagnosis myeloproliferative disorder 2 . Any clinically significant illness surgery within 4 week prior dose 3 . Systemic infection , e.g . hepatitis B , hepatitis C , HIV screen 4 . Uncontrolled hypertension ( systolic &gt; 150 mmHg diastolic &gt; 100 mmHg , clinically significant ( i.e . active ) cardiovascular disease : CVA/stroke ( ≤ 3 month prior enrolment ) , myocardial infarction ( ≤ 3 month prior enrolment ) , significant coronary artery stenosis , unstable angina , New York Heart Association ( NYHA ) Class 2 great Congestive heart failure , serious cardiac arrhythmia require medication . 5 . Previous treatment Interferon PV 6 . Concurrent treatment cytoreductive agent Hydroxyurea investigational agent type 7 . History malignant disease , include solid tumour haematological malignancy ( except basal cell squamous cell carcinoma skin carcinoma situ cervix completely excise consider cure ) within last 3 year 8 . History severe allergic ( like anaphylaxis ) hypersensitivity reaction ( like angioedema ) , know suspected intolerance investigational product . 9 . Use investigational drug participation investigational drug study within last 4 week 10 . Clinically significant history know presence psychiatric disorder , include limited depression , anxiety sleep disorder 11 . Organ transplant , past plan 12 . Inadequate liver function define serum ( total ) bilirubin &gt; 2,5 x ULN and/ AST ALT &gt; 2,5 x ULN 13 . Clinically significant ECG finding 14 . History renal disease require haemodialysis seizure disorder require anticonvulsant therapy 15 . Pregnant lactating female ( pregnancy test assess within 7 day prior study treatment start ) 16 . Acute chronic infection autoimmune disease ( collagen disease , polyarthritis , immune thrombocythemia , thyroiditis , psoriasis , lupus nephritis autoimmune disorder ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>